The Cooper Companies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COO research report →
Range $59 – $75
Price Chart
About the company
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses.
- CEO
- Albert G. White
- IPO
- 1983
- Employees
- 15,000
- HQ
- San Ramon, CA, US
AI snapshot
Six angles, distilled from the data.
The stock is still rebuilding after a long drawdown from its 52-week high of 89.83, but it has recovered well off the 52-week low of 51.01. Price remains below the 200-day average of 67.96 while holding above the 50-day average of 58.49, a classic early-recovery regime rather than a confirmed long-term uptrend.
Street sentiment is constructive but cautious: the consensus rating is Buy, with a 65.11 target versus a 62.65 last close. Recent changes skew defensive, with several target cuts and downgrades in September, followed by a new Equal Weight call at Barclays and a neutral stance from Piper Sandler.
The earnings profile is strong: COO has beaten EPS in 7 of the last 7 reported quarters, including a 3.6% beat in September and an 11.0% beat in June. Next-year EPS is modeled higher at 4.69 from 2.91 TTM, so shareholders should watch whether margin discipline keeps that upgrade path intact.
Recent insider activity leans positive, with five open-market director purchases and no open-market sales. The buying came from multiple directors in meaningful size, while the award and exempt transactions look like routine compensation-related noise rather than a directional signal.
Profitability is solid, with a 65.9% gross margin and 13.46% net margin supporting respectable cash generation. Revenue growth is modest at 0.6% year over year, but earnings growth is much stronger at 357.1%, and free cash flow reached 1.16 billion in fiscal 2025.
COO screens as a quality healthcare supplier with better margin structure than many med-tech peers, though growth is not explosive. The valuation is not stretched on earnings, at 13.74x P/E, and the setup favors a company that can convert steady execution into multiple recovery.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.20B
- P/E
- 20.59
- Fwd P/E
- 12.58
- PEG
- 0.47
- P/S
- 2.71
- P/B
- 1.40
- EV/EBITDA
- 15.23
- Div Yield
- 0.00%
- Gross Margin
- 63.64%
- Op Margin
- 12.85%
- Net Margin
- 13.46%
- ROE
- 6.88%
- ROIC
- 4.76%
Latest fiscal year · YoY change
- Revenue
- $4.09B+5.1%
- Gross Profit
- $2.48B-4.3%
- Op Income
- $682.90M
- Net Income
- $374.90M-4.4%
- EPS
- $1.88-4.6%
- OCF Growth
- +12.2%
- FCF Growth
- +50.5%
- 52W High
- $89.83
- 52W Low
- $51.01
- 50D MA
- $58.26
- 200D MA
- $67.57
- Beta
- 0.82
- RSI (14)
- 42
- Avg Volume
- 3.54M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CooperCompanies beat expectations again, posted record free cash flow, and kept CooperSurgical while resetting CooperVision for a healthier 2027 channel and better execution.· September 9, 2026
- Consolidated revenue was $1.066 billion, up about 1% reported and organic; non-GAAP EPS rose 4% to $1.15.
- Gross margin was 66.7%, down 60 bps, while operating margin improved 30 bps to 26.3% on productivity gains.
- Free cash flow hit a quarterly record of $273 million; year-to-date free cash flow was $528 million, up 86%.
- CooperVision revenue was $717 million, essentially flat, but management said U.S. channel destocking and legacy hydrogel rationalization pressured results.
- CooperSurgical revenue was $349 million, up 3% organically, with fertility up 5% to $141 million and strong operating leverage.
- The board completed the strategic review and chose to keep CooperSurgical; management will focus on organic growth, capital allocation, and buybacks.
Third-quarter consolidated revenue was $1.066 billion, increasing approximately 1% on both a reported and organic basis. Gross margin was 66.7%, down 60 basis points year-over-year, and operating margin was 26.3%, up 30 basis points year-over-year. Non-GAAP EPS increased 4% to $1.15, including about $0.03 from tariff refunds. CooperVision revenue was $717 million, essentially flat year-over-year; CooperSurgical revenue was $349 million, up 3% organically, with fertility at $141 million, up 5%. Free cash flow was $273 million, the highest quarterly free cash flow in company history, and year-to-date free cash flow was $528 million, up 86%. For Q4, management guided to consolidated revenue of $1.057 billion to $1.08 billion, organic growth of 0% to 2%, CooperVision revenue of $692 million to $706 million, and CooperSurgical revenue of $364 million to $374 million. Q4 non-GAAP EPS is expected to be $1.05 to $1.09, and free cash flow is expected to be around $170 million, excluding litigation-related payments of roughly $272 million. For fiscal 2027, management said the scheduled GILTI increase should lift the non-GAAP tax rate from roughly 15.5% this year to roughly 17.5%.
Al White framed the quarter as one with strong earnings, record cash flow, and solid fertility performance, offset by deliberate CooperVision inventory actions. He said the board’s strategic review concluded that shareholders are better served by keeping CooperSurgical, arguing offers did not reflect the business’s long-term value and that the company will now focus on profitable organic growth and share repurchases. His tone was confident but candid, especially on CooperVision, where he said execution at the end of the sales process has lagged and the company is moving faster on sales coverage, marketing, and product launches.
Brian Andrews focused on the financial mechanics: gross margin of 66.7% was down 60 bps from higher costs and FX, while operating margin improved to 26.3% on productivity. He highlighted a discrete tax benefit of about $307 million from the favorable close of HMRC’s examination of the company’s 2021 U.K. IP transfer, which he said should provide meaningful non-GAAP tax benefits for at least 10 more years. He also cited record quarterly free cash flow of $273 million, $445 million of buybacks year to date, leverage below 2x, and a $1 billion increase to the repurchase authorization, leaving about $1.5 billion of capacity.
Analysts pressed management on whether the weaker CooperVision outlook was entirely destocking versus a demand problem. Al White said it was “all destock,” and reiterated that U.S. consumption remained in the mid-single digits and should stay there. Questions also focused on why inventories built up, whether the issue could spill into early 2027, and why EMEA would not be affected; management said they have ring-fenced the issue, that EMEA is more subscription-based, and that the U.S. action should be largely finished in Q4. Analysts also asked about China, where management said MiSight has not gained traction and the market is small, less than 2% of revenues this quarter, with Ortho-K pricing disruption and knockoffs creating a messy backdrop.
The bullish case is that the company says underlying demand is healthy, with U.S. contact lens consumption still growing at a mid-single-digit rate and the inventory reset intended to set up a cleaner 2027. CooperSurgical appears to be gaining share, fertility grew 5%, free cash flow is at record levels, and the tax resolution plus buyback capacity add financial flexibility. Management was also upbeat on MyDay, MiSight, and new launches, saying commercial investments and R&D acceleration should support growth.
The main risk is that CooperVision’s reported growth is still being held back by channel inventory reduction, legacy hydrogel rationalization, and weak execution, and management expects Q4 to remain pressured. Asia Pac, especially China, remains challenged, with MiSight down there and the market described as disjointed and small. Margin pressure could continue in Q4 from higher commercial spending, FX, and lower tariff refunds, and the company would not provide 2027 guidance beyond noting a higher tax rate.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.4%
- Shares Outstanding
- 190.16M
- Float Shares
- 188.94M
of shares held by institutions
689 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for COO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Oct 14, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 21, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 5, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 30, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 17, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 17, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 14, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 9, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 16, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jun 22, 26 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 23.55M | ▼ 425.90K |
| Blackrock, Inc. | 14.40M | ▼ 629.47K |
| Vanguard Capital Management LLC | 12.81M | ▲ 49.10K |
| State Street Corp | 8.86M | ▼ 31.74K |
| Vanguard Portfolio Management LLC | 8.28M | ▼ 392.95K |
| Browning West LP | 6.91M | ▼ 286.80K |
| Price T Rowe Associates Inc | 6.08M | ▲ 499.21K |
| T. Rowe Price Investment Management, Inc. | 5.96M | ▼ 1.47M |
| Fmr LLC | 5.75M | ▲ 4.82M |
| Geode Capital Management, LLC | 5.15M | ▼ 209.39K |
| Franklin Templeton Inc | 5.01M | ▼ 90.73K |
| Arrowstreet Capital, Limited Partnership | 5.00M | ▲ 1.00M |
Held by 1,381 ETFs
Biggest fund positions in COO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 26 | Kurzius Lawrence Erik | buy | 10,000 |
| Sep 14, 26 | Rosebrough Walter M Jr | buy | 3,000 |
| Sep 11, 26 | Rosebrough Walter M Jr | buy | 7,000 |
| Sep 14, 26 | Kurzius Lawrence Erik | buy | 10,000 |
| Sep 11, 26 | Keel Paul A | buy | 4,701.015 |
| Jul 1, 26 | Keel Paul A | other | 2,814 |
| Jul 1, 26 | Keel Paul A | other | 0 |
| Jan 3, 26 | Rosebrough Walter M Jr | other | 832 |
| Apr 1, 26 | Rosebrough Walter M Jr | other | 832 |
| Apr 1, 26 | Rosebrough Walter M Jr | other | 832 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our COO coverage
Recent articles, reports, and earnings notes.

The Cooper Companies (COO): Premium Lens Growth and Value Unlock
Cooper Companies posted 8% revenue growth and 26% non-GAAP EPS growth in Q2, with premium contact lenses and fertility driving the story. A strategic review at CooperSurgical adds a potential value catalyst, while debt and Asia Pacific weakness keep the risk profile moderate.

The Cooper Companies, Inc. (COO) slumps 17.5% after earnings
The Cooper Companies, Inc. (COO) slumps after fiscal Q3 earnings, updated guidance, and a completed strategic review disappointed investors. A small EPS miss, weaker CooperVision revenue, and reduced takeover hopes sparked the sharp extended-hours drop.

The Cooper Companies, Inc. (COO) slumps on Q3 miss
The Cooper Companies, Inc. (COO) slumps after hours after fiscal Q3 results showed an EPS beat but a revenue miss and softer Q4 guidance. Investors are reacting to slowing sales growth and a premium valuation, which could keep pressure on the stock if the decline holds into regular trading.
Want a deeper read on COO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
ROSEN, A LEADING NATIONAL FIRM, Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
newsfilecorp.com · Nov 20
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
newsfilecorp.com · Nov 19
The Cooper Companies, Inc. Investor News: If You Have Suffered Losses in The Cooper Companies, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights
globenewswire.com · Nov 18
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
newsfilecorp.com · Nov 17
The Cooper Companies, Inc. Investor News: If You Have Suffered Losses in The Cooper Companies, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights
globenewswire.com · Nov 15
ROSEN, SKILLED INVESTOR COUNSEL, Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
newsfilecorp.com · Nov 13
The Cooper Companies, Inc. Investor News: If You Have Suffered Losses in The Cooper Companies, Inc., You Are Encouraged to Contact the Rosen Law Firm About Your Rights
globenewswire.com · Nov 12
Rosen Law Firm Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
prnewswire.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 15, 2026 · Live quote · Not investment advice